释放 ангиотензинII受体阻断剂的新疗法潜力
Filippos Panteleimon Chatzipieris1, Kiriaki Mavromoustakou2, John M Matsoukas3,4,5,6
1Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
International journal of molecular sciences
|September 27, 2025
概括
药物重用确定了现有药物的新用途. 原来用于高血压和心力衰竭等心血管疾病的AT1抗剂 (sartan) 在治疗神经退行性疾病,癌症和成方面表现有前途.
科学领域:
- 药理学和药物发现
- 心血管医学 心血管医学
- 神经科学是一个神经科学.
背景情况:
- 制药行业通常为特定疾病开发药物.
- 药物重新定位或重新定位包括为现有药物寻找新的治疗应用.
- 氨酸- ангиотензин- алдостерон系统 (RAAS) 对于调节血压和管理诸如高血压和心力衰竭等心血管疾病至关重要.
研究的目的:
- 探索药物重定向的潜力,用于新的治疗应用.
- 调查AT1抗剂 (sartan) 的扩大治疗范围,超出其主要适用范围.
- 突出RAAS在各种病理状况中的作用.
主要方法:
- 对现有药物重定向研究的文献综述.
- 对AT1抗剂及其作用机制的研究分析.
- 检查将RAAS调制与各种疾病联系在一起的证据.
主要成果:
- AT1抗剂在治疗除了心血管疾病之外的疾病方面表现出潜在的有效性.
- 新兴研究表明,沙坦可以对抗神经退行性疾病,癌症和骨关节炎.
- 有证据表明,沙坦可以帮助管理甲基和阿片类药物成.
结论:
- 药物再利用提供了一种有价值的策略,以最大限度地提高已批准药物的治疗潜力.
- AT1抗剂代表了一类有前途的药物,可以在多种疾病领域重新使用.
- 通过重新定位的药物,如萨坦,准RAAS可能为复杂的健康挑战提供新的治疗途径.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
Antihypertensive Drugs: Action of β1 Blockers
1.9K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.9K


